Urgent

HIV in pregnancy - intrapartum management & PMTCT

PMTCT · Obstetric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Prevention of vertical transmission relies on maternal ART (all pregnant women, any CD4/VL, start ASAP), mode of delivery guided by viral load, intrapartum IV zidovudine when indicated, and infant prophylaxis. For a woman presenting in labour these are time-critical decisions; <1% transmission is achievable with suppression.

Red flags

  • Viral load >1000 or unknown in labour
  • Not on ART / late presenter
  • Acute or primary HIV in pregnancy
  • Preterm or prolonged rupture of membranes with high VL
  • Unbooked woman in labour with unknown HIV status

Assessment

Differential diagnosis

  • Known HIV in labour
  • Unbooked/unknown HIV status in labour (offer rapid HIV test)
  • Acute/primary HIV in pregnancy

Investigations

  • Most recent maternal HIV RNA viral load (within 4 weeks of delivery - drives management)
  • If status unknown: offer rapid HIV test in labour
  • CD4 count
  • Current ART regimen and adherence
  • Gestational age

Management

  • Continue maternal ART through labour/delivery
  • Check VL: >1000 copies/mL (or not on ART/late presenter/non-adherent) -> prelabour cesarean at 38 weeks + IV zidovudine
  • VL <=1000 on ART -> vaginal delivery acceptable; cesarean only for obstetric indications
  • Start IV zidovudine >=3 h before a scheduled cesarean, or immediately if presenting in labour with high/unknown VL
  • Avoid fetal scalp electrode, artificial rupture of membranes, and instrumental delivery if VL >=50
  • Ensure infant ARV prophylaxis (neonatal/paediatric protocol)
  • Advise against breastfeeding if not virally suppressed / not on ART (resource-available settings)

Drugs & doses

Continue maternal ART regimen throughout labour/delivery
IV zidovudine 2 mg/kg loading dose (over 1 h) then continuous infusion 1 mg/kg/hour until delivery - if VL >=1000 within 4 weeks, unknown VL, poor adherence, or acute/primary HIV in pregnancy; give regardless of ZDV resistance
Start IV zidovudine at least 3 hours before a scheduled cesarean; start immediately if in labour
IV zidovudine NOT required if VL <=50 consistently with no adherence/resistance concerns; individualise if VL 50-1000
Oral zidovudine must NOT be substituted for IV intrapartum zidovudine
Preferred antenatal ART (for context): 2 NRTIs (TAF/FTC preferred, or TDF/FTC) + an integrase inhibitor (bictegravir preferred - one pill once daily; dolutegravir); boosted darunavir if cabotegravir-PrEP exposure pending genotype
Infant ARV prophylaxis per neonatal protocol (doses not detailed in source)

Disposition

Admit under obstetrics + HIV/ID; liaise neonatology for infant prophylaxis; postpartum - continue ART, adherence support, contraception/family planning.

Complications & pitfalls

  • Vertical HIV transmission
  • Prematurity (PPROM)
  • Postpartum ART non-adherence (pooled adherence only ~53%)

Exam pearls

  • Mode of delivery is driven by VL within 4 weeks of delivery, not by HIV status alone - cesarean adds no benefit if VL <=1000 on ART
  • IV zidovudine is given even if the virus is zidovudine-resistant
  • Do not breastfeed if not virally suppressed/not on ART (resource-available settings); if suppressed, transmission is <1% but not zero - shared decision
  • US National Perinatal HIV Consultation hotline: 1-888-448-8765

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.